Regulators should apply PP (precautionary principle) with care:
This article was originally published in Clinica
Is the precautionary principle, which allows member states to withdraw devices from their markets, compatible with scientific and technological progress? This is a question the medical devices industry has been encouraged to ponder. Research Commissioner at the European Commission, Philippe Busquin, said that some regulatory authorities are too zealous in applying this instrument. They should carefully analyse the degree of risk and then introduce proportionate measures that put the degree of risk and interest into perspective, he said in a speech to the Free University of Brussels at the end of March. He also proposed that there should be the possibility to review measures in the light of further information and transparency.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.